27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Depression is an accepted risk factor for dementia, but it is unclear if this relationship is causal. 3 key findings →
Design: longitudinal study Participants: 388 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau217 showed larger fold-changes and better accuracy for detecting AD pathology in symptomatic individuals, with greater cross-platform agreement than other p-tau variants. 2 key findings →
Design: case-control study Participants: 40 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Aβ-PET was abnormal in 81 participants from J-TRC and 71 participants from BioFINDER. 2 key findings →
Design: cross-sectional Participants: 474 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The primary constituents of plaques (Aβ42/Aβ40) and neurofibrillary tangles (tau and phosphorylated forms of tau [ptau]) are the current leading diagnostic and prognostic cerebrospinal fluid (CSF) biomarkers for AD. 3 key findings →
Design: case-control study Participants: 5,161 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Overall the study included 199 participants with iRBD, 20 hyposmic participants with available dopamine transporter single-photon emission computed tomography, 146 nonmanifest GBA1N409S gene carriers, 21 GBA1N409S gene carrier patients with PD, 50 patients with sporadic PD, and 140 healthy controls. 3 key findings →
Design: cross-sectional Participants: 170 Evidence: low
Full summary, score breakdown and related studies → Original source
We demonstrated that peripherin is distributed in sciatic nerve, and to a lesser extent spinal cord tissue lysates, but not in brain or extra-neural tissues. 3 key findings →
Design: longitudinal study Participants: 45 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau217 may capture earlier Alzheimer's disease (AD)-related cognitive and brain atrophy hallmarks in females compared to males, possibly reflective of increased susceptibility to AD pathophysiology. 2 key findings →
Design: longitudinal study Participants: 163 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Stratification by self-reported recovery revealed that deficits were only detectable in SARS-CoV-2 positive individuals who did not feel recovered from COVID-19, whereas individuals who reported full recovery showed no deficits. 2 key findings →
Design: cohort study Participants: 1,737 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These three main clusers were confirmed in a testing sample. 5 key findings →
Design: cohort study Participants: 9,804 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The SmartPrompt is a smartphone-based reminder application informed by a neuropsychological model of functional disability. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Genetic variants that modify brain gene expression may also influence risk for human diseases. 5 key findings →
Participants: 197 Evidence: low
Full summary, score breakdown and related studies → Original source
This study sets out to identify novel susceptibility genes for late-onset Alzheimer's disease (LOAD) in a powerful set of samples from the UK and USA (1808 LOAD cases and 2062 controls). 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
We identify common genetic variants associated with cognitive performance using a two-stage approach, which we call the proxy-phenotype method. 4 key findings →
Participants: 106,736 Evidence: low
Full summary, score breakdown and related studies → Original source
We demonstrate that using additional phenotype data previously collected by genetic studies to tackle phenotypic heterogeneity in MDD can successfully lead to the discovery of genetic risk factor despite reduced sample size. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Amyloid chronicity provides unique information about cognitive decline and neurofibrillary tangle development and may be useful to investigate preclinical Alzheimer's disease. 2 key findings →
Design: longitudinal study Participants: 257 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We found little evidence to support wide-ranging effects of statins on health outcomes beyond their established beneficial effect on vascular disease. 4 key findings →
Design: cohort study Participants: 129,288 Evidence: high
Full summary, score breakdown and related studies → Original source
Late-life depression is associated with significant cognitive impairment. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's disease, a progressive neurodegenerative pathology, is characterized by the accumulation of Amyloid-β plaques in the brain. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
In this FTIH study the Fc-inactivated anti-Aβ mAb GSK933776 engaged its target in plasma and CSF without causing brain ARIA-E/H in patients with mild AD or MCI. 1 key finding →
Design: open-label trial Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
The steady-state plasma PK results were closely aligned with the previous 2-week PK in the ALZ-801 phase 1b study in APOE4 carrier subjects with AD, as well as a phase 1 7-day PK study in heathy elderly volunteers. 5 key findings →
Design: longitudinal study Participants: 24 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Subtraction MRI has potential as a visual aid increasing the sensitivity of ARIA-E assessment. 3 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
We concluded that liraglutide improves cognitive decline in patients with type 2 diabetes mellitus. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognition averaged 0.8 MMSE (mini-mental state examination) points better (95% CI 0.5-1.2; p<0.0001) and functionality 1.0 BADLS points better (0.5-1.6; p<0.0001) with donepezil over the first 2 years. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The results of this trial support the hypothesis that memantine treatment leads to functional improvement and reduces care dependence in severely demented patients. 5 key findings →
Participants: 166 Evidence: low
Full summary, score breakdown and related studies → Original source
There is a lack of midlife specific data, limited data on VaD, and a lack of geographical representation for many risk factors for dementia. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →